ArticleOncoTargets and therapy2021

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma.

Dan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.